Sight Sciences (SGHT) to Post Earnings on Wednesday

Sight Sciences (NASDAQ:SGHT) is expected to be issuing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Sight Sciences to post earnings of ($0.15) per share and revenue of $21.6940 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Sight Sciences (NASDAQ:SGHT) last announced its earnings results on Wednesday, May 6th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.05). Sight Sciences had a negative net margin of 46.83% and a negative return on equity of 52.34%. The firm had revenue of $19.70 million during the quarter, compared to analyst estimates of $18.46 million. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Sight Sciences Price Performance

NASDAQ SGHT opened at $5.53 on Tuesday. The firm’s fifty day simple moving average is $5.12 and its two-hundred day simple moving average is $4.91. The company has a current ratio of 5.86, a quick ratio of 5.48 and a debt-to-equity ratio of 0.68. Sight Sciences has a 12-month low of $3.19 and a 12-month high of $9.24. The firm has a market capitalization of $300.89 million, a P/E ratio of -7.79 and a beta of 2.38.

Insider Activity at Sight Sciences

In other Sight Sciences news, CEO Paul Badawi sold 28,684 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $5.42, for a total transaction of $155,467.28. Following the sale, the chief executive officer owned 6,122,472 shares of the company’s stock, valued at approximately $33,183,798.24. The trade was a 0.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jeremy B. Hayden sold 12,733 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.51, for a total transaction of $70,158.83. Following the completion of the transaction, the insider directly owned 357,037 shares of the company’s stock, valued at approximately $1,967,273.87. This represents a 3.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 58,566 shares of company stock worth $318,827 in the last quarter. 30.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Sight Sciences

Hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets lifted its position in Sight Sciences by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after acquiring an additional 3,785 shares during the period. O Shaughnessy Asset Management LLC purchased a new stake in Sight Sciences during the 4th quarter valued at about $81,000. Tower Research Capital LLC TRC increased its holdings in shares of Sight Sciences by 32.7% in the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after purchasing an additional 2,875 shares during the period. The Manufacturers Life Insurance Company acquired a new position in shares of Sight Sciences in the fourth quarter valued at about $96,000. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of Sight Sciences in the fourth quarter worth about $107,000. 55.51% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on SGHT shares. Weiss Ratings lowered Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 11th. UBS Group initiated coverage on Sight Sciences in a research note on Tuesday, July 28th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Citigroup upped their target price on Sight Sciences from $5.15 to $6.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Sight Sciences has an average rating of “Hold” and an average target price of $7.75.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.